The DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
NRF2 and cancer: the good, the bad and the importance of context
Open accessAbstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“Potent protection against aflatoxin‐induced tumorigenesis through induction of Nrf2‐regulated pathways by the triterpenoid1‐ [2‐cyano‐3‐,12‐dioxooleana‐1,9(11)‐dien‐28‐oyl]”
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003) · Nature Genetics · doi:10.1038/ng1248 · Cited by 883
Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Calabrese, V., Cornelius, C., Dinkova-Kostova, A. T., Calabrese, E. J., & Mattson, M. P. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3074 · Cited by 796
Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., & Lozniewski, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112203099 · Cited by 795
Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
McMahon, M. J., Itoh, K., Yamamoto, M. P., Chanas, S. A., Henderson, C. J., McLellan, L. I., Wolf, C. R., Cavin, C., & Hayes, J. D. (2001) · PubMed · Cited by 651
Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., & Yamamoto, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-08 · Cited by 638
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637
Self-citationNuclear Factor κB Is a Molecular Target for Sulforaphane-mediated Anti-inflammatory Mechanisms
Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., & Gerhäuser, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104794200 · Cited by 632
Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth
Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5003 · Cited by 629
When NRF2 Talks, Who's Listening?
Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S., & Kensler, T. W. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3216 · Cited by 595
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 569
Self-citationCancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway
Hayes, J. D., McMahon, M., Chowdhry, S., & Dinkova-Kostova, A. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3221 · Cited by 539
Miao, W., Hu, L., Scrivens, P. J., & Batist, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412081200 · Cited by 535
Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity
Yamamoto, T., Suzuki, T., Kobayashi, A., Wakabayashi, J., Maher, J., Motohashi, H., & Yamamoto, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01704-07 · Cited by 513
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
Orchestrating Redox Signaling Networks through Regulatory Cysteine Switches
Paulsen, C. E., & Carroll, K. S. (2010) · ACS Chemical Biology · doi:10.1021/cb900258z · Cited by 476
Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., & Hirohashi, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.082 · Cited by 468
Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling
Nathan, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18174 · Cited by 456
The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy
Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D. (2010) · Diabetes · doi:10.2337/db09-1342 · Cited by 440
The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative Disease
Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J. A., Williamson, T. P., Kraft, A. D., Lee, J.-M., Li, J., & Johnson, J. A. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2242 · Cited by 438
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Sun, Z., Chin, Y. E., & Zhang, D. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01639-08 · Cited by 414
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
Self-citationOoi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401
KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ
Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.025 · Cited by 399
Palsamy, P., & Subramanian, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.03.008 · Cited by 380
Xu, C., Huang, M.-T., Shen, G., Yuan, X., Lin, W., Khor, T. O., Conney, A. H., & Kong, A.-N. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0300 · Cited by 380
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
Thiol-Based Redox Switches and Gene Regulation
Antelmann, H., & Helmann, J. D. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3400 · Cited by 365
Redox Regulation by Keap1 and Nrf2 Controls Intestinal Stem Cell Proliferation in Drosophila
Hochmuth, C. E., Biteau, B., Bohmann, D., & Jasper, H. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.006 · Cited by 362
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H. S., Yoo, N. J., & Lee, S. H. (2010) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 358
Kawai, Y., Garduño, L., Theodore, M., Yang, J., & Arinze, I. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208173 · Cited by 353
Sussan, T. E., Rangasamy, T., Blake, D. J., Malhotra, D., El-Haddad, H., Bedja, D., Yates, M. S., Kombairaju, P., Yamamoto, M., Liby, K. T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804333106 · Cited by 346
Self-citationHayes, J. D., Chanas, S. A., Henderson, C. J., McMahon, M., Sun, C., Moffat, G. J., Wolf, C. R., & Yamamoto, M. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280033 · Cited by 320
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer
Khor, T. O., Huang, M.-T., Prawan, A., Liu, Y., Hao, X., Yu, S., Cheung, W. K. L., Chan, J. Y., Reddy, B. S., Yang, C. S., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0028 · Cited by 306
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 305
Zhang, D. D., Lo, S.-C., Sun, Z., Habib, G. M., Lieberman, M. W., & Hannink, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501279200 · Cited by 298
High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286
Shin, S., Wakabayashi, J., Yates, M. S., Wakabayashi, N., Dolan, P. M., Aja, S., Liby, K. T., Sporn, M. B., Yamamoto, M., & Kensler, T. W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.022 · Cited by 275
Self-citationKeap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Fountzilas, E., Francoeur, N., Sanisetty, S., Grammatikos, A. P., Hecht, J. L., & Cannistra, S. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4668 · Cited by 270
Yates, M. S., Tran, Q. T., Dolan, P. M., Osburn, W. O., Shin, S., McCulloch, C. C., Silkworth, J. B., Taguchi, K., Yamamoto, M., Williams, C. R., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp100 · Cited by 269
Self-citationHypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues
Wang, R., An, J., Ji, F., Jiao, H., Sun, H., & Zhou, D. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.004 · Cited by 259
Conaway, C. C., Wang, C.-X., Pittman, B., Yang, Y.-M., Schwartz, J. E., Tian, D., McIntee, E. J., Hecht, S. S., & Chung, F.-L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0237 · Cited by 240
Nrf2 protects against airway disorders
Cho, H.-Y., & Kleeberger, S. R. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.024 · Cited by 239
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
Shaw, A. T., Winslow, M. M., Magendantz, M., Ouyang, C., Dowdle, J., Subramanian, A., Lewis, T. A., Maglathin, R. L., Tolliday, N., & Jacks, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105941108 · Cited by 230
Dinkova-Kostova, A. T., Jenkins, S. N., Fahey, J. W., Ye, L., Wehage, S. L., Liby, K. T., Stephenson, K. K., Wade, K. L., & Talalay, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.09.012 · Cited by 230
Self-citationNrf2 Expression Is Regulated by Epigenetic Mechanisms in Prostate Cancer of TRAMP Mice
Yu, S., Khor, T. O., Cheung, K.-L., Li, W., Wu, T.-Y., Huang, Y., Foster, B. A., Kan, Y. W., & Kong, A.-N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008579 · Cited by 228
Genetic Analysis of Cytoprotective Functions Supported by Graded Expression of Keap1
Taguchi, K., Maher, J. M., Suzuki, T., Kawatani, Y., Motohashi, H., & Yamamoto, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01591-09 · Cited by 225
Regulation of Notch1 Signaling by Nrf2: Implications for Tissue Regeneration
Wakabayashi, N., Shin, S., Slocum, S. L., Agoston, E. S., Wakabayashi, J., Kwak, M.-K., Misra, V., Biswal, S., Yamamoto, M., & Kensler, T. W. (2010) · Science Signaling · doi:10.1126/scisignal.2000762 · Cited by 224
Kim, J.-E., You, D.-J., Lee, C., Ahn, C., Seong, J. Y., & Hwang, J.-I. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.06.004 · Cited by 222
NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease
Boutten, A., Goven, D., Artaud-Macari, E., Boczkowski, J., & Bonay, M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.006 · Cited by 221
Sudarshan, S., Sourbier, C., Kong, H.-S., Block, K., Romero, V. A. V., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00483-09 · Cited by 217
Somatic mutations of the KEAP1 gene in common solid cancers
Yoo, N. J., Kim, H. R., Kim, Y. R., An, C. H., & Lee, S. H. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04178.x · Cited by 216
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Neymotin, A., Calingasan, N. Y., Wille, E., Naseri, N., Petri, S., Damiano, M., Liby, K. T., Risingsong, R., Sporn, M., Beal, M. F., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.027 · Cited by 210
Self-citationEgner, P. A., Chen, J. G., Wang, J. B., Wu, Y., Sun, Y., Lu, J. H., Zhu, J., Zhang, Y. H., Chen, Y. S., Friesen, M. D., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0296 · Cited by 208
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung
Satoh, H., Moriguchi, T., Taguchi, K., Takai, J., Maher, J. M., Suzuki, T., Winnard, P. T., Raman, V., Ebina, M., Nukiwa, T., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq105 · Cited by 197
Yates, M. S., Kwak, M.-K., Egner, P. A., Groopman, J. D., Bodreddigari, S., Sutter, T. R., Baumgartner, K. J., Roebuck, B. D., Liby, K. T., Yore, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3823 · Cited by 191
Self-citationHu, R., Saw, C. L.-L., Yu, R., & Kong, A.-N. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3276 · Cited by 187
Tufekci, K. U., Civi Bayin, E., Genc, S., & Genc, K. (2011) · Parkinson's Disease · doi:10.4061/2011/314082 · Cited by 182
Mechanism of Chemical Activation of Nrf2
Li, Y., Paonessa, J. D., & Zhang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035122 · Cited by 179
Aleksunes, L. M., Goedken, M. J., Rockwell, C. E., Thomale, J., Manautou, J. E., & Klaassen, C. D. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170084 · Cited by 178
Stack, C., Ho, D., Wille, E., Calingasan, N. Y., Williams, C., Liby, K., Sporn, M., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 169
Self-citationHu, R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl049 · Cited by 163
The Disulfide Proteome and Other Reactive Cysteine Proteomes: Analysis and Functional Significance
Lindahl, M., Mata‐Cabana, A., & Kieselbach, T. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3551 · Cited by 160
Shen, G., Khor, T. O., Hu, R., Yu, S., Nair, S., Ho, C.-T., Reddy, B. S., Huang, M.-T., Newmark, H. L., & Kong, A.-N. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1112 · Cited by 160
Wu, Q., Wang, Y., Senitko, M., Meyer, C. J., Wigley, W. C., Ferguson, D. A., Grossman, E. B., Chen, J., Zhou, X. J., Hartono, J. R., et al. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00353.2010 · Cited by 158
Osburn, W. O., Yates, M. S., Dolan, P. D., Chen, S., Liby, K. T., Sporn, M. B., Taguchi, K., Yamamoto, M., & Kensler, T. W. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn079 · Cited by 158
Self-citationYamadori, T., Ishii, Y., Homma, S., Morishima, Y., Kurishima, K., Itoh, K., Yamamoto, M. P., Minami, Y., Noguchi, M., & Hizawa, N. (2012) · Oncogene · doi:10.1038/onc.2011.628 · Cited by 156
Wei, Y., Gong, J., Yoshida, T., Eberhart, C. G., Xu, Z., Kombairaju, P., Sporn, M. B., Handa, J. T., & Duh, E. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.026 · Cited by 145
Self-citationNegi, G., Kumar, A., Joshi, R. P., & Sharma, S. S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.087 · Cited by 144
Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 135
Kensler, T. W., Ng, D., Carmella, S. G., Chen, M., Jacobson, L. P., Muñoz, A., Egner, P. A., Chen, J. G., Qian, G. S., Chen, T. Y., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr229 · Cited by 128
Merchant, A. A., Singh, A., Matsui, W. H., & Biswal, S. S. (2011) · Blood · doi:10.1182/blood-2011-05-355362 · Cited by 126
O′Flaherty, L., Adam, J., Heather, L. C., Zhdanov, A. V., Chung, Y., Miranda, M. X., Croft, J., Olpin, S. E., Clarke, K., Pugh, C. W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq305 · Cited by 118
Dumont, M., Wille, E. J., Calingasan, N. Y., Tampellini, D., Williams, C. R., Gouras, G. K., Liby, K. T., Sporn, M. B., Beal, M. F., & Lin, M. T. S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05970.x · Cited by 112
Self-citationSulforaphane prevents mouse skin tumorigenesis during the stage of promotion
Gills, J. J., Jeffery, E. H., Matusheski, N. V., Moon, R. C., Lantvit, D. D., & Pezzuto, J. M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.007 · Cited by 112
Kinch, L. N., Grishin, N. V., & Brugarolas, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.005 · Cited by 111
Spencer, S. R., Wilczak, C. A., & Talalay, P. (1990) · PubMed · Cited by 102
Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR
Yore, M. M., Kettenbach, A. N., Sporn, M. B., Gerber, S. A., & Liby, K. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022862 · Cited by 99
Self-citationSynthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer
Liby, K. T., Royce, D. B., Risingsong, R., Williams, C. R., Maitra, A., Hruban, R. H., & Sporn, M. B. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0197 · Cited by 90
Self-citationYou, A., Nam, C.-W., Wakabayashi, N., Yamamoto, M. P., Kensler, T. W., & Kwak, M.-K. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.034 · Cited by 88
Dickinson, S. E., Melton, T., Olson, E. R., Zhang, J., Saboda, K., & Bowden, G. T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0770 · Cited by 86
McGrath‐Morrow, S. A., Lauer, T., Yee, M., Neptune, E., Podowski, M., Thimmulappa, R. K., O’Reilly, M. A., & Biswal, S. S. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90487.2008 · Cited by 78
Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer
Takahashi, T., Sonobe, M., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Nagai, S., Sato, K., Miyahara, R., Okubo, K., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21520 · Cited by 78
Perera, R. M., & Bardeesy, N. M. (2011) · Nature · doi:10.1038/475043a · Cited by 73
Kim, H., Jung, Y., Shin, B. S., Kim, H., Song, H., Bae, S. H., Rhee, S. G., & Jeong, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126839 · Cited by 60
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Yamasaki, T., Tran, T. A. T., Öz, O. K., Raj, G. V., Schwarz, R. E., DeBerardinis, R. J., Zhang, X., & Brugarolas, J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.234 · Cited by 58
CDDO-Methyl Ester Delays Breast Cancer Development in Brca1-Mutated Mice
Kim, E., Deng, C., Sporn, M. B., Royce, D. B., Risingsong, R., Williams, C. R., & Liby, K. T. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0359 · Cited by 57
Self-citationCurcumin Chemoprevention: The Long Road to Clinical Translation
Shureiqi, I., & Baron, J. A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0060 · Cited by 41
Thiol-based redox signalling: Rust never sleeps
Wouters, M. A., Iismaa, S. E., Fan, S. W., & Haworth, N. L. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.002 · Cited by 34
Bui, C., & Shin, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.101 · Cited by 19
Kuroda, K., Kanisawa, M., & Akao, M. (1982) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/69.6.1317 · Cited by 17
TGF-β can leave you breathless
Qian, B.-F., & Wahl, S. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.04.001 · Cited by 14
Kuroda, K., Terao, K., & Akao, M. (1983) · PubMed · Cited by 12
McCarthy, N. J. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3119 · Cited by 11
Cited by
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
“By contrast, high levels of ROS generation due to loss of NRF2 lead to elevated levels of pro-inflammatory cytokines [101].”
BackgroundInfluentialThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Sies, H., Berndt, C., & Jones, D. P. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045037 · Cited by 3,520
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.